Find Reports

Select Report Type

Reimbursement Review

Displaying 276 - 300 of 1422

Please scroll or swipe to the right to view the full content.

Title	Brand Name	Generic Name	Files	Therapeutic Area	Recommendation Type	Status	Submission Date	Recommendation Date Sort ascending	Project Number
Colorectal Cancer			Final Report	Colorectal Cancer		Complete		Nov 12, 2021	PH0005-000
Trientine Hydrochloride	MAR-Trientine	Trientine Hydrochloride	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Stakeholder feedback on Draft Recommendation	Wilson's Disease	Reimburse with clinical criteria and/or conditions	Complete	Apr 19, 2021	Nov 11, 2021	SR0680-000
romosozumab	Evenity	romosozumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Osteoporosis, postmenopausal women	Reimburse with clinical criteria and/or conditions	Complete	Feb 1, 2021	Nov 11, 2021	SR0676-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Classical Hodgkin lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Jan 29, 2021	Nov 1, 2021	PC0236-000
azacitidine	Onureg	azacitidine	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Acute myeloid leukemia	Reimburse with clinical criteria and/or conditions	Complete	Mar 1, 2021	Oct 20, 2021	PC0245-000
Decitabine-Cedazuridine (Inqov...	Inqovi	Decitabine-Cedazuridine	Decitabine-Cedazuridine (Inqovi) for MDS - pERC Final Recommendation Decitabine-Cedazuridine (Inqovi) for MDS - Final Economic Guidance Report Decitabine-Cedazuridine (Inqovi) for MDS - Final Clinical Guidance Report Decitabine-Cedazuridine (Inqovi) for MDS - pERC Initial Recommendation Decitabine-Cedazuridine (Inqovi) for MDS - PAG Feedback on Initial Recommendati…Decitabine-Cedazuridine (Inqovi) for MDS - Manufacturer Feedback on Initial Rec…Decitabine-Cedazuridine (Inqovi) for MDS - Patient Advocacy Group Feedback on I…Decitabine-Cedazuridine (Inqovi) for MDS - Clinician Feedback on Initial Recomm…Decitabine-Cedazuridine (Inqovi) for MDS - Patient Advocacy Group COI Declarati…Decitabine-Cedazuridine (Inqovi) for MDS - Clinician COI Declarations	Myelodysplastic Syndromes (MDS)	Reimburse with clinical criteria and/or conditions	Complete	Oct 9, 2020	Sep 22, 2021	PC0228-000
elexacaftor / tezacaftor / iva...	Trikafta	elexacaftor / tezacaftor / ivacaftor and ivacaftor	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Cystic fibrosis, F508del CFTR mutation	Reimburse with clinical criteria and/or conditions	Complete	Jan 22, 2021	Sep 16, 2021	SR0673-000
budesonide/ glycopyrronium /fo...	Breztri Aerosphere	budesonide/ glycopyrronium /formoterol fumarate	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	chronic obstructive pulmonary disease (COPD)	Reimburse with clinical criteria and/or conditions	Complete	Jan 28, 2021	Sep 14, 2021	SR0675-000
larotrectinib	Vitrakvi	larotrectinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Solid tumours with NTRK gene fusion	Reimburse with clinical criteria and/or conditions	Complete	Nov 16, 2020	Sep 13, 2021	PC0221-000
incobotulinumtoxinA	Xeomin	incobotulinumtoxinA	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Chronic sialorrhea associated with neurological disorders	Reimburse with clinical criteria and/or conditions	Complete	Feb 26, 2021	Sep 9, 2021	SR0678-000
risperidone	Perseris	risperidone	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Stakeholder feedback on Draft Recommendation	Schizophrenia, adults	Reimburse with clinical criteria and/or conditions	Complete	Jan 29, 2021	Sep 8, 2021	SR0671-000
givosiran	Givlaari	givosiran	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Acute hepatic porphyria (AHP) in adults	Reimburse with clinical criteria and/or conditions	Complete	Feb 23, 2021	Sep 8, 2021	SR0679-000
liraglutide	Saxenda	liraglutide	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Stakeholder feedback on Draft Recommendation	Chronic weight management in adults	Do not reimburse	Complete	Dec 23, 2020	Sep 1, 2021	SR0668-000
risdiplam	Evrysdi	risdiplam	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Spinal muscular atrophy	Reimburse with clinical criteria and/or conditions	Complete	Nov 19, 2020	Aug 26, 2021	SR0661-000
daunorubicin and cytarabine	Vyxeos	daunorubicin and cytarabine	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Acute myeloid leukemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 22, 2021	Aug 24, 2021	PC0237-000
brexucabtagene autoleucel	Tecartus	brexucabtagene autoleucel	Recommendation and Reasons Clinical, Pharmacoeconomic, and Ethics combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Mantle cell lymphoma	Reimburse with clinical criteria and/or conditions	Complete	Dec 18, 2020	Aug 24, 2021	PG0219-000
human insulin	Entuzity KwikPen	human insulin	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Diabetes mellitus	Reimburse with clinical criteria and/or conditions	Complete	Jan 27, 2021	Aug 23, 2021	SR0672-000
venetoclax	Venclexta	venetoclax	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Acute myeloid leukemia	Do not reimburse	Complete	Jan 22, 2021	Aug 23, 2021	PC0239-000
budesonide	Jorveza	budesonide	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Stakeholder feedback on Draft Recommendation	Maintenance of Eosinophilic esophagitis in adults	Reimburse with clinical criteria and/or conditions	Complete	Nov 5, 2020	Aug 23, 2021	SR0666-000
upadacitinib	Rinvoq	upadacitinib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Stakeholder feedback on Draft Recommendation	Psoriatic Arthritis, adults	Reimburse with clinical criteria and/or conditions	Complete	Jan 4, 2021	Aug 20, 2021	SR0658-000
venetoclax	Venclexta	venetoclax	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submissions Clinician Input Stakeholder feedback on Draft Recommendation	Acute myeloid leukemia	Reimburse with clinical criteria and/or conditions	Complete	Jan 8, 2021	Aug 20, 2021	PC0238-000
nivolumab-ipilimumab	Opdivo-Yervoy	nivolumab-ipilimumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Malignant Pleural Mesothelioma (MPM)	Reimburse with clinical criteria and/or conditions	Complete	Oct 9, 2020	Aug 4, 2021	PC0229-000
pembrolizumab	Keytruda	pembrolizumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Colorectal cancer	Reimburse with clinical criteria and/or conditions	Complete	Nov 30, 2020	Jul 27, 2021	PC0235-000
durvalumab	Imfinzi	durvalumab	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Extensive-stage small cell lung cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 1, 2020	Jul 27, 2021	PC0234-000
encorafenib	Braftovi	encorafenib	Recommendation and Reasons Clinical and Pharmacoeconomic combined Report Patient Group Input Submission Clinician Input Stakeholder feedback on Draft Recommendation	Metastatic colorectal cancer	Reimburse with clinical criteria and/or conditions	Complete	Dec 16, 2020	Jul 26, 2021	PC0233-000

Health Technology Review

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 276 - 300 of 600

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Sub Line	Status	Project Number
Utilization of Old versus New Generation Biologics for Public and Private Insurers in Canada	Utilization of Old versus New Generation Biologics for Public and Private Insur…Infographic - Biologics for Plaque Psoriasis	Jun 13, 2022	Technology Review	Completed	HC0020-000
Dapagliflozin for Chronic Kidney Disease	Dapagliflozin for Chronic Kidney Disease	Jun 10, 2022	Rapid Review with Expert Input		RD0065-000
Melatonin for the Treatment of Insomnia in Children and Adolescents	Melatonin for the Treatment of Insomnia in Children and Adolescents	Jun 10, 2022	Rapid Review	Completed	RC1423-000
Systemic Thrombolysis by Alteplase for Acute Ischemic Stroke	Systemic Thrombolysis by Alteplase for Acute Ischemic Stroke	Jun 8, 2022	Rapid Review with Expert Input	Completed	RD0066-000
Monitoring Patients With Psychotic Disorders for Clozapine-Induced Myocarditis or Cardiomyopathy	Monitoring Patients With Psychotic Disorders for Clozapine-Induced Myocarditis …	Jun 6, 2022	Rapid Review		RC1429-000
Guidelines for Pediatric Immune Thrombocytopenia	Guidelines for Pediatric Immune Thrombocytopenia	Jun 3, 2022	Rapid Review		RC1426-000
CADTH and the Canadian Institute for Health Information (CIHI) Real-World Evidence Feasibility Collaboration	CIHI (PPD001) - GLP1 for feedback.pdf	Jun 1, 2022	Technology Review	Completed	CP0027 - HC0019
Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Refractory or High-Risk Patients	Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Refracto…	May 31, 2022	Rapid Review	Completed	RC1430-000
Stepped Care Models for Chronic Pain	Stepped Care Models for Chronic Pain	May 30, 2022	Technology Review	Completed	HC0034-000
Reconsolidation and Consolidation Therapies for the Treatment and Prevention of Post-Traumatic Stress Disorder	Reconsolidation and Consolidation Therapies for the Treatment and Prevention of…	May 26, 2022	Rapid Review	Completed	RC1424-000
Robotic-Assisted Spinal Surgery	Robotic-Assisted Spinal Surgery	May 24, 2022	Rapid Review		RC1427-000
Melatonin for the Treatment of Insomnia: A 2022 Update	Melatonin for the Treatment of Insomnia: A 2022 Update	May 24, 2022	Rapid Review	Completed	RC1422-000
Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Following Retinal Detachment Surgery	Dexamethasone Intravitreal Implant for the Treatment of Macular Edema Following…	May 20, 2022	Rapid Review		RC1428-000
Pre-Surgical Screening Tools and Risk Factors for Chronic Post-Surgical Pain	Pre-Surgical Screening Tools and Risk Factors for Chronic Post-Surgical Pain	May 17, 2022	Technology Review	Completed	HC0023-000
Melatonin for the Treatment or Prevention of Delirium	Melatonin for the Treatment or Prevention of Delirium	May 17, 2022	Rapid Review	Completed	RC1421-000
Clinical Effectiveness of Second Generation Injectable Antipsychotics	Clinical Effectiveness of Second Generation Injectable Antipsychotics	May 12, 2022	Rapid Review	Completed	RC1418-000
Cost-Effectiveness of Treatment for Pediatric Immune Thrombocytopenia	Cost-Effectiveness of Treatment for Pediatric Immune Thrombocytopenia	May 5, 2022	Rapid Review	Completed	RC1425-000
Management of HIV in Primary Care Settings	Management of HIV in Primary Care Settings	May 4, 2022	Technology Review	Completed	HC0028-000
Hub-and-Spoke Models of Care for Chronic Pain	Hub-and-Spoke Models of Care for Chronic Pain	May 2, 2022	Technology Review	Completed	HC0030-000
Pharmacological Therapies for COVID-19	Pharmacological Therapies for COVID-19	Apr 27, 2022	Technology Review
Enablers for Remote Monitoring Programs for Cardiac Conditions: Lessons From the COVID-19 Pandemic	Enablers for Remote Monitoring Programs for Cardiac Conditions: Lessons From th…	Apr 22, 2022	Policy Insight	Completed	CY0014-000
Evusheld (Tixagevimab and Cilgavimab) for the Pre-exposure Prophylaxis of COVID-19 in Adults and Adolescents (≥ 12 Years of Age and Weighing at Least 40 kg)	Evusheld (Tixagevimab and Cilgavimab) for the Pre-exposure Prophylaxis of COVID…	Apr 21, 2022	Technology Review	Completed	HD0008-000
Systemic Thrombolysis and Endovascular Therapy for Large Vessel Occlusion Acute Ischemic Stroke	Systemic Thrombolysis and Endovascular Therapy for Large Vessel Occlusion Acute…	Apr 21, 2022	Rapid Review with Expert Input		RD0067-000
Radioiodine Resensitization for Radioiodine Refractory Metastatic Differentiated Thyroid Cancer	Radioiodine Resensitization for Radioiodine Refractory Metastatic Differentiate…	Apr 15, 2022	Rapid Review	Completed	RC1419-000
Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder	Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder	Apr 14, 2022	Rapid Review	Completed	RC1420-000

Horizon Scan

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 101 - 110 of 110

Projects in Progress

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 26 - 27 of 27

View All Reports

Filter

Project Sub Line

Last Updated

Min

Max

Items per page

Export to CSV

Displaying 276 - 300 of 2132

Please scroll or swipe to the right to view the full content.

Title	Files	Last Updated Sort ascending	Project Line	Project Sub Line	Status	Project Number
Benchmarking CT and MRI exams		Nov 21, 2024	Health Technology Review		In Progress	CM0016-000
Optimal Wait Times		Nov 21, 2024	Health Technology Review		In Progress	CM0014-000
pembrolizumab	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation Patient and Clinician Group input	Nov 21, 2024	Reimbursement Review		Complete	PC0344-000
Long-Acting Inhaled Drugs for Chronic Obstructive Pulmonary Disease		Nov 15, 2024	Health Technology Review	Therapeutic Review	Active	TR0016-000
Adult Classical Hodgkin Lymphoma	Final Report	Nov 15, 2024	Reimbursement Review	Provisional Funding Algorithm	Complete	PH0052-000
Federal, Provincial, and Territorial Coverage of Diagnostic Sleep Studies		Nov 13, 2024	Health Technology Review	Environmental Scan	Completed	ES0382-000
pembrolizumab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Nov 12, 2024	Reimbursement Review		Complete	PC0343-000
elranatamab	Recommendation and Reason Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Nov 12, 2024	Reimbursement Review		Complete	PC0315-000
aflibercept 8mg/0.07mL	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation	Nov 7, 2024	Reimbursement Review		Complete	SR0812-000
Midazolam Compared With Lorazepam in Adults to Control Seizures	Midazolam Compared With Lorazepam in Adults to Control Seizures	Nov 6, 2024	Health Technology Review	Rapid Review	Completed	RC1554-000
Utilization of Long-Acting Injectable Antipsychotics		Nov 1, 2024	Health Technology Review	Technology Review	In Progress	HC0098-000
Pharmaceutical Reviews Update — Issue 52		Oct 31, 2024	Reimbursement Review	Pharmaceutical Review Update
epcoritamab	Recommendation and Reasons Patient and Clinician Group input Clinical and Pharmacoeconomic Combined Report Feedback on Draft Recommendation	Oct 31, 2024	Reimbursement Review		Complete	PC0334-000
everolimus	Recommendation and Reasons Clinical and Pharmacoeconomic Combined Report Responses to Questions From the Drug Programs Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	SX0814-000
rivaroxaban	Recommendation and Reason Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	SX0750-000 - SR0750-000
eltrombopag	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	SX0777-000
Nab-paclitaxel	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0354-000
nab-paclitaxel	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0360-000
Pembrolizumab	Recommendation and Reason Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	PX0346-000
Nivolumab and Ipilimumab	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic combined Report Stakeholder Input	Oct 30, 2024	Reimbursement Review		Complete	PX0347-000
Nab-paclitaxel	Recommendation and reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Patient and Clinician Group Input	Oct 30, 2024	Reimbursement Review		Complete	PX0348-000
bevacizumab and lomustine	Recommendation and Reasons Responses to Questions From the Drug Programs Clinical and Pharmacoeconomic Combined Report Stakeholder Input - Clinicians Stakeholder Input - Industry Stakeholder Feedback on Draft Recommendation	Oct 30, 2024	Reimbursement Review		Complete	PX0318-000
Review of Guidelines on Bupropion for Depression	Review of Guidelines on Bupropion for Depression	Oct 30, 2024	Health Technology Review	Rapid Review	Completed	RC1558-000
GLP-1 Receptor Agonists and Self-Harm		Oct 29, 2024	Health Technology Review	Observational Study	Active	OS0009-000
relugolix	Recommendation and Reason Clinical and Pharmacoeconomic Combined Report Stakeholder feedback on Draft Recommendation Patient and Clinician Group input	Oct 29, 2024	Reimbursement Review		Complete	PC0342-000